299 related articles for article (PubMed ID: 32511835)
1. Validation of the Italian version of the Charcot-Marie-Tooth Health Index.
Pisciotta C; Ciafaloni E; Zuccarino R; Calabrese D; Saveri P; Fenu S; Tramacere I; Genovese F; Dilek N; Johnson NE; Heatwole C; Herrmann DN; Pareyson D;
J Peripher Nerv Syst; 2020 Sep; 25(3):292-296. PubMed ID: 32511835
[TBL] [Abstract][Full Text] [Related]
2. Validation of the Italian version of the Charcot-Marie-Tooth disease Pediatric Scale.
Zuccarino R; Prada V; Moroni I; Pagliano E; Foscan M; Robbiano G; Pisciotta C; Cornett K; Shy R; Schenone A; Pareyson D; Shy M; Burns J
J Peripher Nerv Syst; 2020 Jun; 25(2):138-142. PubMed ID: 32394473
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Italian version of the pediatric CMT quality of life outcome measure.
Moroni I; Danti FR; Pareyson D; Pagliano E; Piscosquito G; Foscan M; Marchi A; Ardissone A; Genitrini S; Wu TT; Shy ME; Ramchandren S
J Peripher Nerv Syst; 2022 Jun; 27(2):127-130. PubMed ID: 35416371
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease.
Cornett KM; Menezes MP; Bray P; Halaki M; Shy RR; Yum SW; Estilow T; Moroni I; Foscan M; Pagliano E; Pareyson D; Laurá M; Bhandari T; Muntoni F; Reilly MM; Finkel RS; Sowden J; Eichinger KJ; Herrmann DN; Shy ME; Burns J;
JAMA Neurol; 2016 Jun; 73(6):645-51. PubMed ID: 27043305
[TBL] [Abstract][Full Text] [Related]
5. [The application of scales and characteristics of disability in the common genotypes of Charcot-Marie-Tooth disease].
Liu X; Zhang RX; Liu L; Xie YZ; Lin ZQ; Zhao Q; Cao WQ; Zhu XY; Li XB
Zhonghua Yi Xue Za Zhi; 2021 Jan; 101(2):131-136. PubMed ID: 33455129
[No Abstract] [Full Text] [Related]
6. Reliability of the Charcot-Marie-Tooth functional outcome measure.
Bray P; Cornett KMD; Estilow T; Pareyson D; Zuccarino R; Skorupinska M; Pipis M; Sowden JE; Scherer S; Reilly MM; Shy ME; Herrmann DN; Burns J; Eichinger KJ
J Peripher Nerv Syst; 2020 Sep; 25(3):288-291. PubMed ID: 32844461
[TBL] [Abstract][Full Text] [Related]
7. Validation of a new hand function outcome measure in individuals with Charcot-Marie-Tooth disease.
Prada V; Robbiano G; Mennella G; Hamedani M; Bellone E; Grandis M; Schenone A; Zuccarino R
J Peripher Nerv Syst; 2020 Dec; 25(4):413-422. PubMed ID: 33140522
[TBL] [Abstract][Full Text] [Related]
8. The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM).
Eichinger K; Burns J; Cornett K; Bacon C; Shepherd ML; Mountain J; Sowden J; Shy R; Shy ME; Herrmann DN
Neurology; 2018 Oct; 91(15):e1381-e1384. PubMed ID: 30232254
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of the Charcot-Marie-Tooth Disease Infant Scale.
Mandarakas MR; Menezes MP; Rose KJ; Shy R; Eichinger K; Foscan M; Estilow T; Kennedy R; Herbert K; Bray P; Refshauge K; Ryan MM; Yiu EM; Farrar M; Sampaio H; Moroni I; Pagliano E; Pareyson D; Yum SW; Herrmann DN; Acsadi G; Shy ME; Burns J; Sanmaneechai O
Brain; 2018 Dec; 141(12):3319-3330. PubMed ID: 30476010
[TBL] [Abstract][Full Text] [Related]
10. The Charcot-Marie-Tooth Health Index: Evaluation of a Patient-Reported Outcome.
Johnson NE; Heatwole C; Creigh P; McDermott MP; Dilek N; Hung M; Bounsanga J; Tang W; Shy ME; Herrmann DN
Ann Neurol; 2018 Aug; 84(2):225-233. PubMed ID: 30014533
[TBL] [Abstract][Full Text] [Related]
11. [Validation of the Spanish version of the Charcot-Marie-Tooth disease Pediatric Scale (CMTPedS)].
Pitarch-Castellano I; Argente-Escrig H; Frasquet M; Damià-Vidal M; Canet-Barrera A; Sevilla T; Burns J
Rev Neurol; 2022 Feb; 74(3):78-82. PubMed ID: 35084732
[TBL] [Abstract][Full Text] [Related]
12. Novel outcome measures for Charcot-Marie-Tooth disease: validation and reliability of the 6-min walk test and StepWatch(™) Activity Monitor and identification of the walking features related to higher quality of life.
Padua L; Pazzaglia C; Pareyson D; Schenone A; Aiello A; Fabrizi GM; Cavallaro T; Santoro L; Manganelli F; Gemignani F; Vitetta F; Quattrone A; Mazzeo A; Russo M; Vita G;
Eur J Neurol; 2016 Aug; 23(8):1343-50. PubMed ID: 27160471
[TBL] [Abstract][Full Text] [Related]
13. Parent-proxy pediatric CMT quality of life outcome measure: Validation of the Italian version.
Danti FR; Pagliano E; Pareyson D; Foscan M; Marchi A; Feoli A; Bruschi F; Piscosquito G; Shy ME; Ramchandren S; Moroni I; Wu TT
J Peripher Nerv Syst; 2024 Mar; 29(1):107-110. PubMed ID: 38329138
[TBL] [Abstract][Full Text] [Related]
14. Validation of the parent-proxy pediatric Charcot-Marie-Tooth disease quality of life outcome measure.
Wu TT; Finkel RS; Siskind CE; Feely SME; Burns J; Reilly MM; Muntoni F; Estilow T; Shy ME; Ramchandren S;
J Peripher Nerv Syst; 2023 Jun; 28(2):237-251. PubMed ID: 36748295
[TBL] [Abstract][Full Text] [Related]
15. Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis.
Sadjadi R; Reilly MM; Shy ME; Pareyson D; Laura M; Murphy S; Feely SM; Grider T; Bacon C; Piscosquito G; Calabrese D; Burns TM
J Peripher Nerv Syst; 2014 Sep; 19(3):192-6. PubMed ID: 25400013
[TBL] [Abstract][Full Text] [Related]
16. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores.
Fridman V; Sillau S; Acsadi G; Bacon C; Dooley K; Burns J; Day J; Feely S; Finkel RS; Grider T; Gutmann L; Herrmann DN; Kirk CA; Knause SA; Laurá M; Lewis RA; Li J; Lloyd TE; Moroni I; Muntoni F; Pagliano E; Pisciotta C; Piscosquito G; Ramchandren S; Saporta M; Sadjadi R; Shy RR; Siskind CE; Sumner CJ; Walk D; Wilcox J; Yum SW; Züchner S; Scherer SS; Pareyson D; Reilly MM; Shy ME;
Neurology; 2020 Mar; 94(9):e884-e896. PubMed ID: 32047073
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of the Pediatric Charcot-Marie-Tooth Disease Quality of Life Outcome Measure.
Ramchandren S; Wu TT; Finkel RS; Siskind CE; Feely SME; Burns J; Reilly MM; Estilow T; Shy ME;
Ann Neurol; 2021 Feb; 89(2):369-379. PubMed ID: 33222249
[TBL] [Abstract][Full Text] [Related]
18. Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure.
Mandarakas MR; Eichinger KJ; Bray P; Cornett KMD; Shy ME; Reilly MM; Ramdharry GM; Scherer SS; Pareyson D; Estilow T; McKay MJ; ; Herrmann DN; Burns J
Neurology; 2024 Feb; 102(3):e207963. PubMed ID: 38237108
[TBL] [Abstract][Full Text] [Related]
19. NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice.
Jennings MJ; Kagiava A; Vendredy L; Spaulding EL; Stavrou M; Hathazi D; Grüneboom A; De Winter V; Gess B; Schara U; Pogoryelova O; Lochmüller H; Borchers CH; Roos A; Burgess RW; Timmerman V; Kleopa KA; Horvath R
Brain; 2022 Nov; 145(11):3999-4015. PubMed ID: 35148379
[TBL] [Abstract][Full Text] [Related]
20. Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.
Mannil M; Solari A; Leha A; Pelayo-Negro AL; Berciano J; Schlotter-Weigel B; Walter MC; Rautenstrauss B; Schnizer TJ; Schenone A; Seeman P; Kadian C; Schreiber O; Angarita NG; Fabrizi GM; Gemignani F; Padua L; Santoro L; Quattrone A; Vita G; Calabrese D; ; Young P; Laurà M; Haberlová J; Mazanec R; Paulus W; Beissbarth T; Shy ME; Reilly MM; Pareyson D; Sereda MW
Neuromuscul Disord; 2014 Nov; 24(11):1003-17. PubMed ID: 25085517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
